IMRT (Intensity modulated radiation therapy) promises more accurate Hodgkin's therapy:
This article was originally published in Clinica
Intensity modulated radiation therapy (IMRT) can improve the treatment of Hodgkin's disease by enabling a more precise delivery of radiation therapy to tumours while reducing exposure to surrounding healthy tissue, according to a US study. The technique conforms radiation energy to the size, shape and location of a tumour, avoiding drawbacks associated with conventional radiation therapies, which can cause damage to the heart, lung and thyroid and increase the risk of breast and lung cancer, says researcher Dr Billy Loo, of Stanford University, California. The findings were presented last week at the American Society for Therapeutic Radiology and Oncology's annual meeting, in New Orleans.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.